Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zapomeran - Arcturus Therapeutics

Next Previous
Drug Profile

Zapomeran - Arcturus Therapeutics

Alternative Names: ARCT-154; Kostaive; Sa-mRNA vaccine - Arcturus Therapeutics; Self-amplifying mRNA vaccine - Arcturus Therapeutics; VBC-COV19-154

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Meiji Seika Pharma; Vinbiocare Biotechnology
  • Class COVID-19 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 26 Aug 2026 Meiji Seika Pharma receives approval for a partial amendment to the manufacturing and marketing approval of KOSTAIVE® for intramuscular injection targeting the Omicron subvariant NB.1.8.1 of COVID-19 in Japan
  • 26 Jun 2026 Meiji Seika Pharma submits an application for a partial amendment to the approval of KOSTAIVE® for intramuscular injection targeting the Omicron subvariant NB.1.8.1 of COVID-19 in Japan
  • 03 Mar 2026 Registered for COVID-2019 infections (Prevention) in United Kingdom (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top